The efficacy of rat MOv18 IgE and the equivalent rat IgG2b was then compared: at a 10 mg/kg fortnightly dose, rat MOv18 IgE was significantly superior at restricting tumour growth (Figure 11c). This evidence concerns the gene IGHE and neoplasm.